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a  b  s  t  r  a  c  t
Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive
accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lym-
phocytes usually inﬁltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The
diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosisKeywords:
Chronic lymphocytic leukemia
is  deﬁned by two staging systems (Rai and Binet) established by physical examination and
blood counts, as well as by several biological and genetic markers. In this update, we  present
the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for the
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Immunophenotyping
Cytogenetics
Staging
Prognosis
diagnosis and treatment of chronic lymphocytic leukemia. The following recommendations
are based on an extensive literature review with the aim of contributing to more uniform
patient care in Brazil and possibly in other countries with a similar social–economic proﬁle.
©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
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hronic lymphocytic leukemia (CLL) is the most common type
f leukemia in adults and accounts for approximately 30% of
ll leukemias in this population group. The annual incidence
f CLL in the United States is approximately 4.6 cases/100,000
ersons per year. The median age at diagnosis is 71 years, and
ver 95% of patients are older than 50 years.1 CLL is less fre-
uent in individuals with Asian and Middle Eastern ancestry.2
t is slightly more  common in males, with a 1.25:1 male:female
atio.3
The etiology of CLL is still unknown. Genetic and environ-
ental factors may have an important role. The low frequency
f CLL in individuals with Eastern ethnicity and the higher
ncidence in family members (5–10%) than other mature B-
ell neoplasms reﬂect the potential importance of a genetic
actor.4 CLL used to be considered a disease of naïve B-cell
ymphocytes however recent studies suggest there is a post-
erminal center origin.5
The clinical presentation at diagnosis is extremely vari-
ble. Approximately 60% of patients are asymptomatic, and
he disease may be suspected after a routine blood count.
hen symptomatic, patients present with vague symptoms
f fatigue or weakness.6
Patients usually have a good performance status at diag-
osis. Lymphadenopathy may be observed in approximately
0% of cases often with cervical and axillary lymph nodes
ilaterally and symmetrically being affected. Splenomegaly is
sually mild to moderate and is observed in approximately
0% of cases; hepatomegaly is less frequent.7,8 Although rare
t diagnosis, as the disease progresses patients can have B
ymptoms, which are deﬁned as unintentional weight loss
f 10% or more  within six month, fever above 38 ◦C for
wo or more  weeks without other evidence of infection, and
ight sweats for more  than a month without evidence of
nfection.
Anemia and thrombocytopenia may be observed in
5–30% of patients. They generally result from bone mar-
ow inﬁltration, although they can also be related to an
utoimmune phenomenon [autoimmune hemolytic ane-
ia  (AIHA), immune thrombocytopenia (ITP), and immune
eutropenia].7,8 Lymphocytosis is always present, but the
bsolute number of lymphocytes is extremely variable. In a
ecent analysis by the Brazilian CLL Registry (unpublished
ata), the median hemoglobin level was 13 g/dL, platelet count
as 180 × 109/L, white blood cell count was 35 × 109/L (range:
–900 × 109/L), and lymphocyte count was 27 × 109/L (range:
.4–891.0 × 109/L) among 1612 Brazilian patients with CLL.Richter Syndrome, which is deﬁned as the transformation
f CLL into an aggressive lymphoma (most commonly dif-
use large B-cell lymphoma) occurs in 5–10% of all cases. The(http://creativecommons.org/licenses/by-nc-nd/4.0/).
syndrome may be suspected if there are signs of aggressive
disease, such as impairment of performance status, presence
of B symptoms, and rapid increase in the size of lymph nodes.1
Infections are common complications of CLL due to
the deﬁciency of both the cellular and humoral immune
system. T cells, natural killer cells, neutrophils, and mono-
cytes/macrophages may be signiﬁcantly compromised.9,10
Furthermore, hypogammaglobulinemia is not rare and can
become more  intense after CLL treatment.11 Although pre-
ventive use of intravenous immunoglobulin is controversial, it
may be necessary if there are severe recurrent infections.12,13
Bacterial infections are common even prior to the treat-
ment of CLL. The most common agents are Streptococcus
pneumoniae, Staphylococcus aureus,  and Haemophilus inﬂuenzae.
Response to immunization is variable, and vaccination should
be carried out early in the disease to obtain the best results.
Live virus vaccines should be avoided.14 Viral infections can
also occur, and special attention should be paid to herpes
zoster reactivation. Fungal infections or opportunistic bacte-
ria, however, are rare in untreated CLL. The introduction of
immunosuppressive drugs signiﬁcantly increases the risk for
cytomegalovirus infections, as well as Pneumocystis jiroveci, Lis-
teria monocytogenes,  and fungal infections.14
Autoimmune complications can occur during the dis-
ease course,15–17 and the most common complication is
AIHA (occurs in approximately 3% of patients with stable
disease). The incidence of AIHA increases with disease pro-
gression (up to 11% in late-stage Binet B and C), and up to
15% of CLL patients may have positive direct antiglobulin
(DAT) or Coombs tests during the disease course, includ-
ing non-anemic patients.18 The diagnosis of AIHA may be
difﬁcult because the reticulocyte count can be low due to
erythroid hypoplasia when bone marrow is extensively inﬁl-
trated by CLL. Increased Lactate dehydrogenase (LDH) levels
may occur as the disease progresses, and other associated
factors, such as impaired hepatic function and bilirubin, may
be preserved with normal liver function. Measurement of
serum haptoglobin may be useful in this setting.17 Other
immune cytopenias can occur less frequently. Clinically sig-
niﬁcant immune thrombocytopenia (2% of CLL patients)
should be suspected when there is a rapid drop in platelets
and no evidence of bone marrow failure.18 Approximately
one third of cases can evolve to Evans syndrome. There
is usually a good response to ﬁrst-line therapy (steroids
or intravenous immunoglobulin), but approximately 20% of
cases are refractory. These patients may beneﬁt from rit-
uximab alone or in association with cyclophosphamide and
dexamethasone. Splenectomy should be reserved for select
refractory cases. Pure red cell aplasia and autoimmune neu-
tropenia can also occur, but these conditions are extremely
rare.18
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Secondary malignancies, such as skin and lung cancer, are
more common in CLL patients than in the general population,
which may be due to immunodeﬁciency.20
Diagnosis
CLL is deﬁned by the presence of at least 5 × 109/L
CD5+/CD23+ monoclonal B lymphocytes in peripheral blood
(PB) for more  than three months,21 with immunophenotyp-
ing of PB being sufﬁcient for diagnosis. Small lymphocytic
lymphoma is distinguishable only by its non-leukemic
appearance and requires the presence of lymphadenopathy
and/or splenomegaly and a clonal B lymphocyte count (CLL
immunophenotype) that does not exceed 5 × 109/L in the PB.22
CLL-type monoclonal B lymphocytosis (MBL) is deﬁned by
the presence of fewer than 5 × 109/L B-cells with the CLL phe-
notype in the PB in the absence of lymphadenopathy, spleen
or hepatic enlargement, cytopenias, and disease-related
symptoms.23 In the 2016 revision of the WHO  classiﬁca-
tion of lymphoid neoplasms, a distinction between low-count
(<0.5 × 109/L) and high-count MBL  (>0.5 × 109/L) was recom-
mended because low-count MBL  has a low probability of
progressing to CLL, while high-count MBL  may progress at
a rate of 1–2% per year.24,25 The incidence of MBL among a
healthy population may vary depending on the sensitivity of
the diagnostic method but can reach up to 12%.26
Morphological evaluation of a blood smear should show
small mature lymphocytes with a narrow cytoplasm, a dense
nucleus with partially aggregated chromatin, and the absence
of visible nucleoli. The percentage of prolymphocytes in blood
lymphocytes may be <55%. A higher percentage would favor
the diagnosis of prolymphocytic leukemia. Gumprecht shad-
ows are frequently found on CLL PB slides.22
CLL lymphocytes exhibit a characteristic proﬁle of CD19+,
CD5+, CD23+, CD20+ low, CD200+, CD22+ low/negative, CD79b+
low/negative, CD43+ low, sIg+ or sIg+ low, sIgM+ low, CD11c+
low/negative, FMC7 negative, CD10 negative, and CD103 neg-
ative.
Matutes et al.27 proposed a scoring system for the diagno-
sis of CLL (modiﬁed in 1997)28 based on the evaluation of ﬁve
parameters: CD5+ (1 point), CD23+ (1 point), FMC7 negative (1
point), weak intensity of kappa/lambda chains (1 point), and
weak or negative CD22/CD79b (1 point). The CLL score ranges
between 5 (typical CLL cases) and 3 (less typical CLL cases).
Scores of 0–2 exclude the diagnosis of CLL.
Classical laboratory markers for adverse prognoses of CLL
are CD38,29 CD49d,30 and ZAP-70.31 The cut-off values for
CD49d and CD38 are at least 30%, while the cut-off for ZAP-70
is not clear and technically controversial.32 The expres-
sions of some markers, such as CD305 (LAIR-1), CCR6, and
CXCR5 are also associated with some high-risk chromosomal
abnormalities.33
Recommendations  of  the  Brazilian  Group  of  CLL  group  for
diagnosis1) Complete blood count and differential white blood cell
count;
2) Morphological evaluation of a blood smear; 2 0 1 6;3  8(4):346–357
3) PB immunophenotyping: at least a 4-color panel of the
ﬂuorochromes FITC, PE, PerCP or PerCPCy5.5, and APC per-
formed according to the consensus of the Brazilian Group
of Flow Cytometry (GBCFLUX) for Chronic Lymphopro-
liferative Disorders (in press). This panel should include
one screening tube (CD8/Lambda, CD56/Kappa, CD19/CD4,
CD3) and two diagnostic tubes, including CD45, CD20,
CD19, CD5, CD79b, CD23, CD19, and CD200. The Brazil-
ian Group of CLL also recommends two additional tubes
for prognostic and minimal residual disease (MRD) pur-
poses, including CD38, CD305, CD19, CD49d, CD81, CD43,
CD19, and sIgM. ZAP-70 is considered an optional progno-
stic marker.
Panels using six, eight, or more  colors should use the
same markers in appropriate combinations. The Euroﬂow
group34 designed an 8-color panel of monoclonal anti-
bodies (MoAbs) to improve diagnosis and to differentiate
CLL from other B cell lymphoproliferative disorders. They
included all MoAbs proposed by Matutes with the excep-
tion of FMC7 and CD22, and they incorporated other
markers such as CD43, CD81, CD38, CD20, and CD200.
CD200 is particularly useful for differentiating CLL from
mantle cell lymphoma.
4) Bone marrow biopsy and aspiration are NOT recommended
for routine CLL diagnosis. This procedure may be per-
formed in patients who will participate in clinical trials
and/or patients with persistent cytopenias after treatment
to differentiate leukemic inﬁltration from therapy-related
toxicity. The bone marrow smear should be characterized
by the presence of CLL cells, the percentage of which is typ-
ically above 30%. Inﬁltration in a bone marrow biopsy may
have a nodular, interstitial, or diffuse growth pattern.
5) Imaging techniques, such as ultrasound, computed
tomography, magnetic resonance imaging, and positron
emission tomography-CT (PET-CT) scanning, are NOT rec-
ommended for routine CLL diagnosis or staging.
Prognosis
Two clinical staging systems (Rai and Binet) were introduced
in the 1970s and are still widely used. They are easy to apply
in the clinical practice, based only on clinical data, and take
into account lymph node, spleen, and liver involvement, as
well as the presence of cytopenias (anemia and thrombocy-
topenia) (Table 1). Some patients in the low-risk group (0–1 Rai
and Binet A) may, however, exhibit rapid disease progression,
while others remain in a stable disease condition for many
years.7,8 Other prognostic factors have been researched in an
attempt to predict disease evolution by taking into account
other clinical and biological prognostic factors. Unfavorable
prognostic factors include male gender, an initial white blood
cell count above 35 × 109/L, lymphocyte doubling time (LDT)
of less than six months, a diffuse histological pattern in bone
marrow inﬁltration35 and elevated levels of beta-2 microglob-
ulin, LDH, serum thymidine, and serum CD23 at diagnosis.36
As previously discussed, high expressions of CD38,29 CD49d,37
CD305,38 and ZAP-70 protein detected by ﬂow cytometry are
also prognostic markers.31 However, these markers are no
rev bras hematol hemoter. 2 0 1 6;3  8(4):346–357 349
Table 1 – Clinical staging and survival.110
BINET staging system
Stage Risk Characteristics % of cases
A Low < three enlarged node sites without anemia or thrombocytopenia 63
B Intermediate ≥ three enlarged node sites without anemia or thrombocytopenia 30
C High Presence of anemia and/or thrombocytopenia a 7
RAI staging system
Stage Risk Characteristics
0 Low Lymphocytosis
I Intermediate Lymphocytosis + node enlargement
II Intermediate Lymphocytosis + palpable spleen and/or liver
III High Lymphocytosis + anemiab
IV High Lymphocytosis + thrombocytopenia b
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b Anemia: Hb < 11 g/dL; thrombocytopenia: <100 × 109/L.
ore  sensitive than clinical staging for determining tumor
urden and predicting disease progression.
Immunoglobulin heavy chain variable region (IGHV)
utation status has an important role in CLL progno-
is. Mutated IGHV is related to an indolent clinical course
nd a ‘non-mutated’ state with a more  aggressive disease
rogression.39,40 However, determining IGHV mutation status
nvolves expensive and labor-intensive molecular techniques,
hich has limited its use in clinical practice.
Chromosomal abnormalities have an important role in
stablishing CLL prognosis. Whenever possible, a G-banding
aryotype should be performed because patients with com-
lex aberrations often present unfavorable outcomes. Given
he difﬁculty in obtaining abnormal metaphases, ﬂuorescence
n situ hybridization (FISH) is more  efﬁcient for ﬁnding major
enetic abnormalities in CLL. Using FISH, cytogenetic changes
ave been found in 80% of cases41; trisomy 12 was reported in
0–20% of cases, deletion of 13q [del(13q14.1)] was reported
n approximately 55% of cases, deletion of 11q [del(11q22-
3)] was reported in 10–25% of cases, and deletion of 17p
del(17p)] (P53 locus) was reported in 5–10% of cases.42 While
el(13q14.1) is related to a more  favorable prognosis, the asso-
iation between trisomy 12 and prognosis is still not clearly
eﬁned,32 and del(11q22-23) associated with bulky disease is
elated to a more  unfavorable outcome. Chemoimmunother-
py with purine analogs seems to overcome the del(11q22-23)
rognostic effect.41,43
In approximately 7% of cases, del(17p) is found at diagno-
is. It is a cytogenetic aberration associated with the worst
LL prognosis and has led clinicians to change their ﬁrst-line
reatment.41 However, not all patients with del(17p13) require
herapy at the time of diagnosis. Only approximately 50% of
reatment-naïve CLL patients with del(17p13) developed pro-
ressive disease that required therapy within 12–18 months,
hile the other half had a relatively stable disease extending
ut to 70 months of follow-up.44
Using Sanger sequencing, several studies reported that
onoallelic mutations in TP53 are associated with poor prog-
osis in CLL and resistance to standard therapy.45,46 TP53
isruption (either by mutation or deletion) is present inapproximately 15% of patients, and some have both the TP53
mutation and del(17p13), as detected by FISH. Some have no
TP53 mutation but have del(17p13) based on FISH analysis, and
some (3–5%) have the TP53 mutation but no del(17p13) based
on FISH. Importantly, these patients had a short OS that was
comparable to the OS of patients with del(17p13) based on
interphase FISH.46–48 Less than 10% of patients present with
a TP53 mutation at diagnosis, while the mutation is present
in up to 50% of cases in pretreated cohorts, including cases of
Richter’s transformation.49
Clone size according to FISH is also extremely relevant
to CLL. As recently shown, patients with ≤20% 17p deletion
nuclei had a longer median time to ﬁrst treatment (TTFT) and
beffer overall survival (OS) from the date of the ﬁrst FISH study
(44 months and 11 years, respectively) and were more  likely to
have an IGHV mutation.50
Despite the lack of disease-deﬁning molecular alterations
in CLL, some recurrent somatic gene mutations, including
mutations in TP53, ATM, NOTCH1, SF3B1,  BIRC3 genes, and oth-
ers, have been described as important prognostic markers and
are potential therapeutic targets. However, only TP53 has been
consistently described as a clear high-risk marker of therapy
refractoriness and early relapse to date, and patients could
beneﬁt from different treatment approaches.25
More recently, the German CLL Study Group proposed
the CLL International Prognostic Index IPI (CLL-IPI), which
combines the most important genetic risk factors (IGHV,
del(17p)/TP53 mutations) with clinical stage, age, and beta-2
microglobulin level.51
Recommendations  of  the  Brazilian  Group  of  CLL  for
prognosis  stratiﬁcation
The recommendations are to investigate the del(17p13) detec-
tion with FISH and test for the TP53 mutation before initiating
ﬁrst-line treatment. Whenever possible, testing for the most
frequent genetic aberrations, such as del(13q), del(11q), +12,
IGHV mutation, and G-banding karyotype, should be per-
formed as well. Moreover, whenever possible during disease
course, the TP53 mutation and 17p deletion should be
oter.350  rev bras hematol hem
investigated by FISH before initiating a new treatment because
there may be clonal selection after the ﬁrst treatment that may
require a change in the treatment paradigm.
Overview  of  minimal  residual  disease
Minimal residual disease (MRD) evaluation after three and six
cycles of therapy regimens and three months after the end
of treatment seems to be an important outcome predictor for
CLL treatment, and it has been increasingly used in conjunc-
tion with the more  traditional endpoints of progression-free
survival (PFS) and OS.52,53
MRD  is also an important predictor of outcome after
hematopoietic stem cell transplantation (HSCT). MRD-
negative status 12 months after HSCT has a high prognostic
signiﬁcance.54 However, this time point must be validated in
prospective clinical trials.
Both immunoglobulin heavy chain (IgH)-PCR and ﬂow
cytometry can be used to asses MRD.  In the European
Research Initiative on CLL (ERIC) study, the ﬂow cytometry
approach was identiﬁed and validated to be reliable in clin-
ical trials and the clinical practice. The use of the MoAb
CD19/CD5/kappa/lambda combination may be important for
identifying cases that do not require extensive analysis for
MRD  detection. These cases must have a CD19+ cell percentage
>9% of total leukocytes, a CD19+ : ratio <0.04:1 or >61:1, and
in cases with sufﬁcient CD5+ B cells for enumeration, >82% of B
cells co-expressing a CD19+CD5+ : ratio of <0.05:1 or >32:1 or
>54% of CD19+CD5+ cells lacking surface immunoglobulin.55
The initial ERIC recommendations were based on a 4-
color panel of monoclonal antibodies (FITC/PE/PerCP/APC):
CD20/CD38/CD19/CD5; CD81/CD22/CD19/CD5 and
CD79b/CD43/CD19/CD5, with a component speciﬁcation
independent of instrument and reagents at the 0.01% (10−4)
level.55
In an effort to quantify CLL cells at a level of 0.001%
(10−5), another ERIC assay was proposed with six mark-
ers (FITC/PE/PerC5.5/PE-Cy7/APC/APC-H7): CD3/CD38/CD5/
CD19/CD79b/CD20 and CD81/CD22/CD5/CD19/CD43/CD20).
Interestingly, this approach correlated well with the 4-color
panel, with good linearity even at 0.001% (10−5) sensitivity.
Recently, the ERIC project validated a reliable approach to eval-
uate MRD  in CLL to a level of 10−5 using an 8-color tube,
with a component speciﬁcation independent of equipment
and reagents. They identiﬁed markers that have a substantial
impact on the ability to detect MRD  and composed a 6-color
core panel (i.e. CD19, CD20, CD5, CD43, CD79b, and CD81),
incorporating CD200 or CD 23 to simplify the diagnosis, or also
testing alternative CLL MRD  markers such as CD160 or ROR1,
which was shown to be a very useful marker to discriminate
normal B cells from CLL cells.56
Raponi et al.57 proposed an 8-color panel for assessing CLL
MRD,  including CD81FITC/CD38PE/CD20PerCP/CD43PECy7/
CD5/APC/CD45APC-cy7/CD19V450/CD3 V500, which has
shown good correlation with the 4-color ERIC approach and
with ASO IgH real-time PCR (RQ-PCR), but it was tested in only
a few patients and has not been validated by other centers.
Although treatment protocols based on anti-CD20 monoclonal 2 0 1 6;3  8(4):346–357
antibodies induce loss of CD20 expression, they do not affect
the performance of ﬂow cytometry MRD  assays.58,59
Recommendations  of  the  Brazilian  Group  of  CLL  for  MDR
evaluation
Time points for MRD  assessment: the recommendations are
to perform MRD evaluation only in the context of translational
research and clinical trials and usually to investigate MRD
three months after completion of therapy regimens intended
to eradicate leukemic clones.
Sample: either PB or bone marrow can be used for MRD
assessment. However, there is a higher probability for BM to be
MRD positive than PB, although the associated clinical signif-
icance is still unknown. Hemodilution and sample cellularity
must be evaluated and taken into account. Sensitivity may be
lower in hypocellular samples.
Acquisition: the number of acquired events in the ﬂow
cytometer must be at least 500,000 total events to achieve a
sensitivity of 10−4 with at least 20 CD19+/CD5+ events needed
to characterize the population being analyzed.
Panel of monoclonal antibodies: the recommendation of
the Brazilian Group of CLL for MRD assessment is to use ERIC
4- or 6-color protocols based on their high reproducibility.
Treatment
With a better understanding of CLL biology, there has been
steady progress in treatment in recent years. Several new
drugs have been approved with different mechanisms of
action.
For both the indication of treatment and evaluation of ther-
apy, the International Workshop on CLL (iwCLL) guidelines
should be used.22,42
Although it cannot be pursued as a treatment goal due to
a lack of data, the importance of MRD assessment is growing
and is correlated with improved PFS and, potentially, OS.54,60
Indications  for  treatment
To date, there is no evidence of a clinical beneﬁt in treating CLL
at diagnosis61 and treatment should be initiated only if there is
a clear indication according to iwCLL criteria.22 It is important
to clarify that all treatment indications should be cautiously
judged as CLL-related. Treatment should be initiated only after
other causes have been excluded, such as infectious diseases
or other neoplastic diseases.
The treatment indications are as follows:
1. Bone marrow failure manifested by the development of
anemia and/or thrombocytopenia;
2. Massive splenomegaly (at least 6 cm below the left costal
margin) that is progressive or symptomatic;
3. Massive lymph node (at least 10 cm in longest diameter) or
a progressive or symptomatic lymph node;4. Progressive lymphocytosis with an increase of more  than
50% within two months or a LDT of less than six months.
LDT can be determined by linear regression extrapola-
tion of absolute lymphocyte counts obtained at intervals
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of two weeks over an observation period of 2–3 months
(this parameter should not be used if the initial lymphocyte
count is less than 30 × 109/L). In addition, factors contribut-
ing to lymphocytosis or lymphadenopathy other than CLL
(e.g., infections) should be excluded.
. Autoimmune disease (anemia and/or thrombocytopenia)
with poor response to corticosteroids or other standard
treatments.
. Constitutional symptoms, which are deﬁned as any of the
following: unintentional weight loss of 10% or more in the
past six months, signiﬁcant fatigue [i.e., Eastern Cooper-
ative Oncology Group (ECOG) of 2 or worse; inability to
work or perform usual activities], fever higher than 38.0 ◦C
for two or more  weeks without evidence of infection, and
night sweats for more  than one month without evidence
of infection.
eﬁnition  of  a  patient’s  ﬁtness
o select the best treatment for each patient, it is impor-
ant to evaluate not only disease stage and cytogenetic
isk but also the patient’s physical condition and comor-
idities. A comorbidity scale can be used to classify
atients as ‘Go-Go’, ‘Slow-Go’, and ‘No-Go’.42 One exam-
le of such a scale is the ‘cumulative illness rating scale’
CIRS).62 In clinical trials, patients with a CIRS score ≤6
nd a normal estimated glomerular ﬁltration rate (creatinine
learance > 70 mL/min/1.73 m2) are considered ‘ﬁt’ for more
ntensive treatments.
hlorambucil
onotherapy with alkylating agents, including chlorambucil,
as been the treatment of choice for many  years61, and this
herapy can still be an option, particularly for elderly and unﬁt
atients for whom current standard treatments are not an
ption. The advantages of chlorambucil include its low cost,
ow toxicity, and convenience of being an oral treatment. The
ain disadvantage is the very low, if any, rate of complete
esponse and the risk of side effects with long-term use, such
s myelodysplasia. Currently, the use of chlorambucil alone is
voided whenever a monoclonal antibody is available.42
urine  analogs
urine analogs are still one of the most important drugs in
he treatment of ﬁt patients, and ﬂudarabine is the most
tudied drug. Response rates with ﬂudarabine monotherapy
ange in different studies from 63 to 73% with approximately
–40% of cases having a complete response, corresponding to a
esponse that is superior to that achieved with chlorambucil.63
ong-term monitoring revealed a better OS for ﬂudarabine,64
lthough a greater OS does not seem to be evident in older
atients.65 Fludarabine monotherapy was also no less effec-
ive than more  intensive regimens associated with alkylating
gents.66,67Combinations of purine analogs and alkylating agents
ave synergistic cytotoxicity in CLL because both chemother-
pies have different mechanisms of action and different
oxicity proﬁles. The combination of ﬂudarabine with 1 6;3  8(4):346–357 351
cyclophosphamide (FC) is the most studied therapy and yields
better overall response (74–94%) and complete remission rates
(23–38%) than other regimens in the pre-rituximab era without
increasing the risk of infection despite a higher incidence of
neutropenia.68–70 Other purine analogs have also been stud-
ied, but there was no signiﬁcant beneﬁt over ﬂudarabine.71
Monoclonal  antibodies:  anti-CD20
In recent decades, the addition of monoclonal antibodies has
changed the treatment of all lymphoproliferative disorders,
including CLL, after the introduction of rituximab in treatment
protocols.
In CLL, rituximab is less active as a single agent than
in other lymphoproliferative disorders, which is probably
because of the low density of CD20 in the cell membrane.
Therefore, higher doses of this monoclonal antibody are rec-
ommended for CLL.72,73 The combination of rituximab with
ﬂudarabine and cyclophosphamide (FCR) has a synergistic
effect and efﬁcacy that has been conﬁrmed in several phase
II studies and retrospective analyses. In the largest phase II
study, FCR resulted in an overall response rate of 95%, com-
plete remission rate of 72%, OS at six years of 77%, and medium
PFS of 80 months.74 These results led the German group to
conduct the CLL8 study that demonstrated the superiority of
FCR compared with FC, with better response rates and bet-
ter PFS rates as well as no increase in toxicity or infection risk.
Subgroup analysis showed beneﬁts for all cytogenetic risk fac-
tors, except for individuals with del17p.43 The same beneﬁcial
results associated with FC were also obtained with second-
line treatment.75 These results made the FCR combination
the treatment of choice for ﬁt patients with CLL. Because
CLL occurs at a high frequency in older patients, an FCR-Lite
scheme has been designed in an attempt to reduce toxicity
while maintaining efﬁcacy. In this combination, ﬂudarabine
dosages are reduced to 20 mg/m2, cyclophosphamide dosages
are reduced to 150 mg/m2 on Days 2–4 in cycle 1 and on Days
1–3 in cycles 2–5, and the dosages are increased for rituximab
(375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 14 of
the ﬁrst cycle and on Days 1 and 14 in all subsequent cycles).
After the six cycles were completed, rituximab was given as a
maintenance therapy at 500 mg/m2 once every three months
until relapse.76
Ofatumumab is another monoclonal antibody that targets
a speciﬁc epitope with increased afﬁnity to CD20 and also with
stronger complement-dependent cytotoxicity (CDC), as well
as antibody-dependent cellular cytotoxicity (ADCC).77 This
drug was approved in Europe and in the United States as a
monotherapy for relapsed or refractory patients. It also has
reasonable response rates in high-risk individuals, including
those who are refractory to ﬂudarabine and alemtuzumab or
refractory to ﬂudarabine and have bulky disease, with overall
response rates of 58% and 47%, respectively.78 In the ﬁrst-line
treatment, the combination with chlorambucil in treatment-
naïve unﬁt elderly patients yielded an excellent response rate
of 82% with a 12% complete response rate.79
Obinutuzumab (GA101) is a humanized monoclonal anti-
body that showed impressive results in animal and pre-clinical
studies, and it has been designed to have greater afﬁn-
ity for the type II CD20 epitope, greater ADCC, and lower
oter.352  rev bras hematol hem
CDC with higher direct cell death induction.80 The CLL11
study showed that the combination of obinutuzumab with
chlorambucil yielded a response rate of 78.4% and a 20.7%
complete response rate, with 19.5% MRD  negativity in CLL
patients not eligible for ﬂudarabine-based treatment. It was
far superior to chlorambucil alone and yielded better response
rates than the combination of rituximab and chlorambucil.81
Obinutuzumab-related infusion reactions occur in nearly 65%
of cases in the ﬁrst cycle (21% grade 3 or 4), which leads to
discontinuation in 7% of patients. The rate of infusion reac-
tions drops to 3% in the second cycle and to less than 1% in
subsequent cycles.
Bendamustine
More  recently, bendamustine, an alkylating agent with purine
analog properties, was compared with chlorambucil in a mul-
ticenter, randomized trial and yielded a better response rate
of 68% with a 31% complete response rate and PFS of 21.6
months. There was no difference in OS.82
Promising results were obtained from the combination of
bendamustine with rituximab (BR) in relapsed CLL patients
at a dose of 70 mg/m2 of bendamustine on Days 1 and 2
and 375 mg/m2 of rituximab on Day 1 of the ﬁrst cycle and
500 mg/m2 in the subsequent cycles, for a total of six cycles
every 28 days.83 When used as ﬁrst-line treatment, the BR
scheme with a higher dose of 90 mg/m2 of bendamustine
yielded a 97% response rate and complete remission rate of
31%. A CLL10 study demonstrated comparable results to FCR
in terms of response rates but with fewer complete remis-
sions. This difference was not conﬁrmed in the sub-analysis of
patients older than 65 years or who  had more  comorbidities.84
Unfortunately, bendamustine is not available in Brazil yet and
is not approved for use.
Alemtuzumab
Alemtuzumab is a humanized monoclonal antibody against
the CD52 antigen with proven activity in CLL. In patients
with advanced-stage disease, alemtuzumab monotherapy
yielded response rates of 30–50%, with a median PFS of 9–15
months after second-line treatment with ﬂudarabine.85–87
Alemtuzumab also has proven effectiveness for both del11q
and del17p.88 In a randomized study, alemtuzumab showed
a higher response rate and better PFS in treatment-naïve
patients than chlorambucil.89 The synergistic activity of alem-
tuzumab with ﬂudarabine was effective and safe in a phase II
study, with a response rate of 83% and complete remission
rate with negative MRD  of 53%.90 In a phase III study, alem-
tuzumab in combination with FC was more  toxic than the
FCR regimen.91 In a phase II study, a combination treatment
of alemtuzumab with FCR demonstrated excellent response
rates of 92%, with 70% of all individuals achieving complete
remission and 57% of del17p individuals achieving complete
remission. This scheme can be an alternative bridge ther-
apy to achieve remission before transplantation in del17p
patients.92 In a multicenter phase II study, the combination of
30 mg  alemtuzumab three times a week with 1.0 g/m2 methyl-
prednisolone (MP) for ﬁve consecutive days every 4 weeks in
TP53-deleted CLL resulted in an overall response rate of 85% 2 0 1 6;3  8(4):346–357
and a complete response rate of 36%. The risk of infection was
age-related and seemed only marginally higher in younger
patients than the infection risk associated with FCR.93
Alemtuzumab is no longer approved for use in Brazil
for CLL and is marketed only for its indication in multiple
sclerosis. However, alemtuzumab is available for patients with
CLL through a compassionate-use program.
Lenalidomide
Lenalidomide is a medication with immunomodulatory and
antiangiogenic effects. It has reasonable response rates
in relapsed patients94,95 and has some activity in del17p
patients.96 Phase II trials demonstrated good synergism with
rituximab.97 An association between rituximab and ﬂudara-
bine is also feasible, although a phase I study yielded ominous
results, with an excess of side effects, myelosuppression and
tumor ﬂares.98
Unfortunately, lenalidomide is not available in Brazil yet
and is not approved for use.
Agents  targeting  B-cell  receptor  signaling
A new therapeutic drug class has shown promising results
when used in conjunction with targeted therapy in CLL. The
most prominent agent in this class seems to be the Bru-
ton’s tyrosine kinase inhibitor ibrutinib. Phase I and phase
II studies have shown a surprising response in relapsed or
refractory patients, including high-risk groups (e.g., del17p
patients or patients who relapsed within 24 months of pre-
vious treatment). PFS and OS at 26 months were 71% and
83%, respectively, and 57% and 70% in patients with del17p,
respectively.99 The phase III RESONATE study included 391
relapsed or refractory patients, including 33% with del17p.
Ibrutinib showed better PFS and OS results than ofatumumab.
The excellent response rates were maintained in high-risk
patients with del17p as well as in patients refractory to purine
analogs. This medication is considered the best choice for
second-line treatment in elderly patients and patients with
comorbidities.100 The presence of lymphocytosis is common
in ibrutinib patients, with peak lymphocytosis usually occur-
ring four weeks after the beginning of treatment, but 80% of
patients have had resolution or at least a 50% decrease in
their lymphocyte count. This decline was faster in patients
with unmutated IgHV.99 Ibrutinib treatment used as ﬁrst-line
treatment was tested in the RESONATE-2 study in elderly
patients and was compared with chlorambucil, yielding excel-
lent results. There was a 86% overall response rate, and OS was
estimated at 24 months to be 98%.101 Combination therapy
with rituximab102 and ofatumumab103 has been performed
in relapsed patients with promising results, even in high-risk
groups. The best approach for using these novel modalities is
still a matter of debate. Ibrutinibe was recently approved in
Brazil, only for relapsed/refractory CLL patients.
Another important medication is an inhibitor of the
class I phosphatidylinositol 3-kinase (PI3K) p110  isoform
called idelalisib. A phase I study in relapsed or refrac-
tory patients showed promising results, and a percentage of
patients showed a partial response with lymphocytosis.104 Its
combination with Rituximab was tested in treatment-naïve
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atients105 and in a relapse context.106 In a phase II study with
delalisib as a ﬁrst-line treatment in elderly patients, com-
ination treatment showed excellent results, with an overall
esponse rate of 96.0% and a complete response rate of 14.1%,
s well as PFS and OS rates at 36 months of 92.9% and 90%,
espectively. The response was maintained in patients with
el17p. The presence of diarrhea or colitis grade 3 or 4 can
imit the use of this medication, mainly because the incidence
f side effects was more  common after multiple months of
reatment.105 Idelalisib is not available in Brazil yet and is not
pproved for use.
cl-2  inhibitors
ther new therapeutic classes include Bcl-2 inhibitors. A
hase I study with Venetoclax (ABT-199) showed excellent
esults, with an overall response rate of 79% and a 20% com-
lete response rate, including 5% negativity for MRD and a PFS
ate at 15 months of 66%. High-risk del17p patients had sim-
lar results, but with less sustained PFS.107 Venetoclax is not
vailable in Brazil yet and is not approved for use.
llogeneic  hematopoietic  stem  cell  transplantation
llogeneic HSCT is effective in CLL as shown by the 10-year
omplete remission rate of 69% and OS of 55% in a cohort of
9 consecutive patients with 20 years of follow up.108 How-
ver, the non-relapse mortality is still in the range of 20% in
ost series.109 An important ﬁnding is that prognostic factors
hat negatively inﬂuence the outcome of CLL under chemoim-
unotherapy, such as unmutated IGHV gene, unfavorable
enetic abnormalities, and purine analog refractoriness, do
ot adversely affect PFS or OS after HSCT.109 Currently, HSCT
s still the only curative option for appropriate candidates
young, ﬁt patients with an adequate donor). As there is no
irect comparison between transplant and the novel agents
ibrutinib, idelalisib, or venotoclax), more  data is needed to
etermine which patients should still be considered for HSCT,
nd which should be considered for prolonged treatment with
ne of these novel agents.
Treatment recommendations are shown schematically
elow. Patients classiﬁed as ‘Go-Go’ should receive combina-
ion therapy with FCR (preferable) or BR (especially for patients
lder than 65 years).
‘Slow-Go’ patients should receive chlorambucil in combi-
ation with an anti-CD20 antibody: rituximab, ofatumumab,
r obinutuzumab (preferable). Alternative schemes include a
udarabine-containing regimen at a reduced dose, such as
CR-lite, or a combination of bendamustine and rituximab.
he treatment goal is to control symptoms.
In patients with symptomatic disease and del17p or TP53
utations, the therapy of choice is a kinase inhibitor, which
s preferably ibrutinib. However, idelalisib in association with
ituximab or the bcl-2 inhibitor venetoclax are acceptable
lternatives if available. Alemtuzumab alone or in combina-
ion with MP  also has good activity and can be used. Allogeneic
SCT should be considered in all patients in good clinical con-
ition and if a matched donor is available. 1 6;3  8(4):346–357 353
The ﬁrst treatment can be repeated if the time to relapse
has extended past 24 months in patients who  received
chemoimmunotherapy.
In patients with refractory CLL or early relapse (<24
months) and in patients with del17p, the treatment should
be changed.
The therapy of choice is ibrutinib. Alemtuzumab (alone or
in combination with MP), idelalisib plus rituximab (for slow-
go patients), and venetoclax (only in the presence of del17p or
TP53 mutations) are acceptable alternatives, if available. Allo-
geneic HSCT should be considered the only curative option
for all patients in good clinical condition if a matched donor
is available.
Recommendations  of  the  Brazilian  Group  of  CLL  for  ﬁrst
and second-line  treatment
1) First-line treatment:
a) ‘Go-go’ patients:
- First choice: ﬂudarabine, cyclophosphamide, and rit-
uximab (FCR)
• Alternative options: bendamustine and rituximab
(BR)
- Del (17p) or TP53: ibrutinib and consider allogeneic
HSCT
• Alternative options: idelalisib plus rituximab, vene-
toclax, alemtuzumab with or without high-dose
methylprednisolone, rituximab with or without
high-dose methylprednisolone
b) ‘Slow-go’ patients:
-  First choice: anti-CD20 antibody (obinutuzumab, ofa-
tumumab, or rituximab) plus chlorambucil
• Alternative options: FCR-lite, BR.
- Del (17p) or TP53: ibrutinib
• Alternative options: idelalisib plus rituximab,
venetoclax, alemtuzumab high-dose methylpred-
nisolone, rituximab with or without high-dose
methylprednisolone
2) Relapsed ﬁrst-line treatment:
a) Progress after 24 months: repeat ﬁrst-line treatment
(add an anti-CD20 antibody if not used in the ﬁrst-line
treatment)
b) Progress within 24 months:
- ‘Go-go’ patients: ibrutinib
• Alternative options: alemtuzumab with or with-
out methylprednisolone, rituximab with or without
high-dose methylprednisolone, allogeneic HCST,
bendamustine plus rituximab
- ‘Slow-go’ patients: ibrutinib
• Alternative options: idelalisib plus rituximab,
alemtuzumab with or without methylpred-
nisolone, rituximab with or without high-dose
methylprednisolone bendamustine plus rituximab,
FCR-liteConﬂicts  of  interest
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